Plant Advanced Technologies PAT: 2020 Revenue
15 Mars 2021 - 05:02PM
Business Wire
- Annual revenue up 7% to €1.26 million (vs. €1.17 million in
2019)
- Outlook
- A very promising partnership with Clariant
- Expansion of production capacity for rare molecules through
Cellengo, a newly created subsidiary
- New collaboration agreements under development.
- Revenue growth expected for 2021
Regulatory News:
Plant Advanced Technologies PAT (Paris:ALPAT):
Revenue
(€ thousands)
12/31/20 *
12/31/19
1,256**
1,173
* Unaudited ** 2020 revenue is not consolidated and concerns
solely the parent company, PAT SA as such, this presentation
excludes the revenue of its subsidiaries StratiCELL, Temisis,
Cellengo, PAT Zerbaz and Couleurs de Plantes.
PAT (Plant Advanced Technologies) reported revenue for fiscal
2020 of €1,256,000, up marginally 7% in relation to 2019, driven
notably by increased intra-group subcontracting and stability in
asset sales, despite the health crisis.
2020 BUSINESS UPDATE
- The first products originating from the Clariant
partnership, Prenylium™ and Rootness™ Energize, were launched
in 2020 and received numerous international awards.
- Creation of Cellengo, a PAT subsidiary, producing rare
molecules through industrial fermentation technologies. Its
objective is to scale up manufacturing capacity for biomolecules to
become a leading player in the cosmetics, nutraceutical,
pharmaceutical and plant protection markets.
- Clariant is appointed as a new director Following the
decision of the General Meeting of June 30, 2020, Plant Advanced
Technologies PAT has reinforced its governance by appointing
Clariant to the Board of Directors, represented by Ms. Catherine
Breffa.
- Launch of PsoriaCure, the European program for the treatment
of psoriasis The objective of this three-year program is to
discover the mechanism of action of the proprietary first-in-class
compound TEM1657 developed by Temisis for the treatment of
psoriasis. The PsoriaCure consortium also includes StratiCELL,
PAT’s Belgian subsidiary, a key life sciences partner dedicated to
understanding skin biology and pioneering discoveries in
dermo-cosmetic products, the German company PharmBioTec,
specialized in the development of pre-clinical stage drug
candidates, and the University of Lorraine IMoPA-CNRS research
laboratory, specialized in inflammatory signaling networks.
- TEMISIS increases its capital SFHBB (La Société
Financière Hoche Bains-les-Bains) and PAT (Plant Advanced
Technologies) finalized the €1.6 million capital increase in
Temisis, with a pre-money valuation of €40 million. Following the
completion of this transaction, PAT now holds 98.46% of Temisis ’s
capital and SFHBB, 1.54%. The proceeds of this capital increase
will provide Temisis with the resources to complete the preclinical
studies to ensure the development of the TEM1657 anti-psoriasis
drug candidate. As a reminder, the financing needs for the phase 1
clinical trial of this molecule are estimated between €8 million
and €10 million to be financed through future subscriptions.
OUTLOOK
2020 was marked by the COVID-19 pandemic. In this unprecedented
context, all PAT customers remained loyal and certain projects
delayed during this period are expected to be back on track in
2021. On that basis, the Group remains confident about meeting its
growth targets.
It also reaffirms its continuing commitment to its roadmap
for:
- Maintaining efforts to contain costs and preserve cash;
- Deploying its marketing strategy focused on adopting a product
catalog and indirect distribution.
- Continuing internal research and collaborative efforts to
prepare for the launch of new products
In the nutraceutical market, the subsidiary Cellengo, which is
spearheading the development of the fermentation technology-based
production platform for rare molecules, will continue to develop
its first product and for which, a strategic partnership for its
development, marketing and distribution is currently under
discussion.
Finally, concerning the work on SARS-CoV-2, tests are currently
underway for several active components. PAT (Plant Advanced
Technologies) is investigating the research of original antiviral
molecules, complementary to the current vaccination strategies.
FINANCIAL CALENDAR
Before May 1, 2021
May 12, 2021
Before June 30, 2021
About PAT www.plantadvanced.com Plant Advanced
Technologies (PAT) is specialized in the identification,
optimization and production of rare new active plant compounds or
cosmetics, pharmaceutical, nutraceutical and fine chemicals
markets. PAT possesses unique plant-based expertise with a
portfolio of worldwide patents (PAT Target Binding® and Plant
Milking®)
Plant Advanced Technologies is listed on Euronext Growth™- Paris
ISIN : FR0010785790 - Ticker: ALPAT Reuters ALPAT.PA - Bloomberg :
ALPAT : FP
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210315005586/en/
PAT – Investor Relations - Louis-Nicolas Vallas -
Secretary-General -investisseur@plantadvanced.com
FIN’EXTENSO – Media Relations - Isabelle Aprile - +33 6
17 38 61 78 - i.aprile@finextenso.fr
Plant Advanced Technolog... (EU:ALPAT)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Plant Advanced Technolog... (EU:ALPAT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024